Literature DB >> 2824080

Chemical reactivity of cisplatin bound to human plasma proteins.

L Hegedüs1, W J van der Vijgh, I Klein, S Kerpel-Fronius, H M Pinedo.   

Abstract

Human plasma was incubated with cisplatin over 24 h. Ultrafilterable platinum and platinum reactive with DDTC were determined at regular time intervals during incubation. At each time point more platinum reacted with sodium N,N1-diethyldithiocarbamate (DDTC) than was available as ultrafilterable platinum. At 24 h 70% of total platinum (10% ultrafiltrable platinum and 60% protein-bound platinum) reacted with DDTC. This means that cisplatin bound to plasma proteins can--at least in part--still react with strong nucleophiles.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824080     DOI: 10.1007/BF00570487

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Further evaluation of diethyldithiocarbamate as an antagonist of cisplatin toxicity.

Authors:  G R Gale; L M Atkins; E M Walker
Journal:  Ann Clin Lab Sci       Date:  1982 Sep-Oct       Impact factor: 1.256

3.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; A A Hart; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1984-03

4.  Urine analysis of platinum species derived from cis-dichlorodiammineplatinum(II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbamate.

Authors:  S J Bannister; L A Sternson; A J Repta
Journal:  J Chromatogr       Date:  1979-05-21

5.  Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II).

Authors:  S J Bannister; Y Chang; L A Sternson; A J Repta
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

6.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.

Authors:  K Takahashi; T Seki; K Nishikawa; S Minamide; M Iwabuchi; M Ono; S Nagamine; H Horinishi
Journal:  Jpn J Cancer Res       Date:  1985-01
  7 in total
  6 in total

1.  Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery.

Authors:  Pradeep Rajkumar; Binu Susan Mathew; Saikat Das; Rajesh Isaiah; Subashini John; Ratna Prabha; Denise Helen Fleming
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration.

Authors:  G Tredici; S Tredici; D Fabbrica; C Minoia; G Cavaletti
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

Authors:  J D Holding; W E Lindup; C van Laer; G C Vreeburg; V Schilling; J A Wilson; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 4.  Drug-induced ototoxicity. Pathogenesis and prevention.

Authors:  M Y Huang; J Schacht
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

5.  Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

Authors:  P O Mulder; E G de Vries; D R Uges; A H Scaf; D T Sleijfer; N H Mulder
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

6.  The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.

Authors:  J E Melvik; J M Dornish; E O Pettersen
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.